S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Most-Downgraded Stocks  
NASDAQ:AMGN

Amgen - AMGN Stock Forecast, Price & News

$241.75
+0.25 (+0.10%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$239.15
▼
$242.40
50-Day Range
$225.79
▼
$260.97
52-Week Range
$223.30
▼
$296.67
Volume
2.76 million shs
Average Volume
2.61 million shs
Market Capitalization
$129.09 billion
P/E Ratio
19.96
Dividend Yield
3.52%
Price Target
$251.44

Amgen MarketRank™ Forecast

Analyst Rating
Hold
2.15 Rating Score
Upside/​Downside
4.0% Upside
$251.44 Price Target
Short Interest
Healthy
1.43% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.42
Upright™ Environmental Score
News Sentiment
0.59mentions of Amgen in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
7.67%
From $17.73 to $19.09 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

79th out of 996 stocks

Biological Products, Except Diagnostic Industry

13th out of 165 stocks

See Top Rated MarketRank™ Stocks Here

AMGN stock logo

About Amgen (NASDAQ:AMGN) Stock

Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.

Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.

Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.

Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.

In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.

Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.

Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Stock News Headlines

March 28, 2023 | marketbeat.com
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data (AMGN)
Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP
March 21, 2023 | marketbeat.com
These Are The Top 3 Large Caps For Yield And Dividend Growth  (AMGN)
You can use Marketbeat's Dividend Screener to find top dividend growth stocks with yields above 3% and value for investors.
April 2, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
March 14, 2023 | marketbeat.com
Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3 (AMGN)
Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies,
March 31, 2023 | finance.yahoo.com
1 Dividend Growth Stock to Buy Hand Over Fist
March 31, 2023 | americanbankingnews.com
Amgen Inc. (NASDAQ:AMGN) Receives $251.44 Average Price Target from Brokerages
March 30, 2023 | benzinga.com
Amgen Options Traders Betting On Stock Rising This Much By April Expiration
March 30, 2023 | finance.yahoo.com
This Blue Chip Dividend Stock Should Return to Form When the Risk Premium Flips
April 2, 2023 | Weiss Ratings (Ad)
Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
March 29, 2023 | finance.yahoo.com
Selling US$5.2m worth of stock earlier this year was a lucrative decision for Amgen Inc. (NASDAQ:AMGN) insiders
March 27, 2023 | benzinga.com
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
March 24, 2023 | seekingalpha.com
Amgen: Revenue Growth Potentials And Financial Performance
March 23, 2023 | marketwatch.com
AMGN CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Amgen Inc.
March 23, 2023 | benzinga.com
AMGN LAWSUIT ALERT: Levi & Korsinsky Notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
March 23, 2023 | benzinga.com
Amgen Shareholder Action Reminder
March 23, 2023 | stocknews.com
3 High-Quality Stocks to Add to Your Watchlist Now
March 22, 2023 | finance.yahoo.com
Amgen (AMGN) Stock Moves -1.34%: What You Should Know
March 22, 2023 | finance.yahoo.com
Those who invested in Amgen (NASDAQ:AMGN) five years ago are up 59%
March 22, 2023 | finance.yahoo.com
Here's What is Driving Amgen (AMGN) Stock's Outperformance
March 16, 2023 | finance.yahoo.com
UPDATE 2-Amgen to cut 450 jobs in second round of layoffs this year
March 16, 2023 | finance.yahoo.com
Amgen to cut 450 jobs in second round of layoffs this year
March 16, 2023 | finance.yahoo.com
Amgen to cut about 450 jobs in second round of layoffs this year
March 14, 2023 | finance.yahoo.com
Amgen Faces Lawsuit For Hiding Its Stupendous Tax Bill Of $10B
March 14, 2023 | finance.yahoo.com
Amgen is sued for concealing $10.7 billion tax bill from investors
March 14, 2023 | finance.yahoo.com
2 Stocks to Buy Near Their 52-Week Lows That Could Help You Beat The Market
March 13, 2023 | finance.yahoo.com
15 Biggest Retirement Mistakes You Will Regret Forever
March 13, 2023 | stocknews.com
2 Top Biotech Stocks to Buy in March
See More Headlines
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Company Calendar

Last Earnings
2/07/2023
Ex-Dividend for 3/8 Dividend
2/14/2023
Dividend Payable
3/08/2023
Today
4/01/2023
Next Earnings (Estimated)
4/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AMGN
CUSIP
03116210
CIK
318154
Web
www.amgen.com
Phone
(805) 447-1000
Fax
805-447-1010
Employees
25,200
Year Founded
1980

Price Target and Rating

Average Stock Price Forecast
$251.44
High Stock Price Forecast
$294.00
Low Stock Price Forecast
$182.00
Forecasted Upside/Downside
+4.0%
Consensus Rating
Hold
Rating Score (0-4)
2.15
Research Coverage
13 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$12.11
Trailing P/E Ratio
19.96
Forward P/E Ratio
13.64
P/E Growth
1.94
Net Income
$6.55 billion
Net Margins
24.89%
Pretax Margin
27.91%
Return on Equity
359.47%
Return on Assets
15.48%

Debt

Debt-to-Equity Ratio
10.20
Current Ratio
1.41
Quick Ratio
1.10

Sales & Book Value

Annual Sales
$26.32 billion
Price / Sales
4.90
Cash Flow
$24.42 per share
Price / Cash Flow
9.90
Book Value
$6.86 per share
Price / Book
35.24

Miscellaneous

Outstanding Shares
533,980,000
Free Float
531,520,000
Market Cap
$129.09 billion
Optionable
Optionable
Beta
0.65

Social Links


Key Executives

  • Robert A. BradwayRobert A. Bradway
    Chairman, President & Chief Executive Officer
  • Esteban Santos
    Executive Vice President-Operations
  • Peter H. GriffithPeter H. Griffith
    Chief Financial Officer & Executive Vice President
  • Mike Zahigian
    Chief Information Officer & Senior Vice President
  • David M. Reese
    Executive Vice President-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AMGN Stock - Frequently Asked Questions

Should I buy or sell Amgen stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 4 sell ratings, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings or view top-rated stocks.

What is Amgen's stock price forecast for 2023?

13 Wall Street analysts have issued twelve-month target prices for Amgen's stock. Their AMGN share price forecasts range from $182.00 to $294.00. On average, they anticipate the company's share price to reach $251.44 in the next year. This suggests a possible upside of 4.0% from the stock's current price.
View analysts price targets for AMGN or view top-rated stocks among Wall Street analysts.

How have AMGN shares performed in 2023?

Amgen's stock was trading at $262.64 at the start of the year. Since then, AMGN shares have decreased by 8.0% and is now trading at $241.75.
View the best growth stocks for 2023 here.

When is Amgen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our AMGN earnings forecast.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings data on Tuesday, February, 7th. The medical research company reported $4.09 EPS for the quarter, topping analysts' consensus estimates of $4.04 by $0.05. The medical research company had revenue of $6.84 billion for the quarter, compared to analysts' expectations of $6.77 billion. Amgen had a net margin of 24.89% and a trailing twelve-month return on equity of 359.47%. Amgen's revenue for the quarter was down .1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.36 EPS.
Read the conference call transcript.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Tuesday, March 7th. Stockholders of record on Thursday, May 18th will be given a dividend of $2.13 per share on Thursday, June 8th. This represents a $8.52 annualized dividend and a dividend yield of 3.52%. The ex-dividend date of this dividend is Wednesday, May 17th.
Read our dividend analysis for AMGN.

What ETFs hold Amgen's stock?

ETFs with the largest weight of Amgen (NASDAQ:AMGN) stock in their portfolio include VanEck Biotech ETF (BBH), iShares Biotechnology ETF (IBB), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Dynamic Pharmaceuticals ETF (PJP), Invesco Dynamic Biotechnology & Genome ETF (PBE) and Global X Dow 30 Covered Call ETF (DJIA).

Is Amgen a good dividend stock?

Amgen (NASDAQ:AMGN) pays an annual dividend of $8.52 per share and currently has a dividend yield of 3.53%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 70.36%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 44.63% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY 2023 earnings guidance on Tuesday, January, 31st. The company provided EPS guidance of $17.40-$18.60 for the period, compared to the consensus earnings per share estimate of $17.68. The company issued revenue guidance of $26.00 billion-$27.20 billion, compared to the consensus revenue estimate of $26.25 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $241.75.

How much money does Amgen make?

Amgen (NASDAQ:AMGN) has a market capitalization of $129.09 billion and generates $26.32 billion in revenue each year. The medical research company earns $6.55 billion in net income (profit) each year or $12.11 on an earnings per share basis.

How many employees does Amgen have?

The company employs 25,200 workers across the globe.

Does Amgen have any subsidiaries?
The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More
How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The official website for the company is www.amgen.com. The medical research company can be reached via phone at (805) 447-1000, via email at investor.relations@amgen.com, or via fax at 805-447-1010.

This page (NASDAQ:AMGN) was last updated on 4/2/2023 by MarketBeat.com Staff